ARTICLE | Market Access
Biogen’s Viehbacher on Leqembi’s future
Full approval will unlock reimbursement and energize Alzheimer’s R&D, but the launch will be slow
July 7, 2023 11:00 PM UTC
BioCentury wrote in March that Biogen CEO Chris Viehbacher has a tiger by the tail. With this week’s full approval of Leqembi for Alzheimer’s disease, his grip has tightened.
In an interview with BioCentury the day after FDA converted the accelerated approval of Leqembi lecanemab-irmb to a full approval, Viehbacher paused to recognize the significance of the moment, and discussed how Biogen Inc. (NASDAQ:BIIB) and Eisai Co. Ltd. (Tokyo:4523) plan to commercialize the drug. ...